Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder Cancer

July 2nd 2020

Anant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.

Dr. Catenacci on the Challenges of Developing Novel Therapies in Gastroesophageal Cancer

July 2nd 2020

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Dr. Abou-Alfa on Key Eligibility Criteria for the PROOF Trial in Cholangiocarcinoma

July 2nd 2020

Ghassan K. Abou-Alfa, MD, discusses key eligibility criteria for the phase 3 PROOF trial in cholangiocarcinoma.

Maintenance Olaparib Maintains Benefit in Metastatic Pancreatic Cancer, Regardless of Age

July 2nd 2020

The safety and efficacy of maintenance olaparib in patients with BRCA1/2-mutated metastatic pancreatic cancer proved to be consistent irrespective of age, according to results of a subgroup analysis from the pivotal phase 3 POLO trial.

Real-World Data Indicate Favorable Efficacy With Nivolumab in Advanced Gastric Cancer

July 2nd 2020

Yu Sunakawa, MD, PhD, further discusses the early real-world data from the DELIVER trial with nivolumab in patients with gastric/GEJ cancer and provided insight into what future analyses will examine.

Efficacy With Entrectinib in NTRK+ GI Cancers Indicates a Need for More Molecular Testing

July 1st 2020

Manish R. Patel, DO, further discusses next steps for entrectinib, as well as the need for genetic testing to identify uncommon gene rearrangements in GI malignancies.

Durvalumab/Tremelimumab Combo Could Expand Frontline Options in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from a study of combination durvalumab and tremelimumab, as well as the clinical need for alternative combination regimens in advanced hepatcellular carcinoma.

Frontline NALIRIFOX Regimen Shows Promising Activity, Tolerability in Pancreatic Cancer

July 1st 2020

The regimen of liposomal irinotecan plus 5-fluorouracil/leucovorin plus oxaliplatin demonstrated a tolerable safety profile with promising antitumor activity when used as frontline treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

Atezolizumab/Bevacizumab Shows Comparable Activity in Older Patients With Advanced HCC

July 1st 2020

The combination of atezolizumab and bevacizumab demonstrated comparable clinical activity and safety versus sorafenib in older and younger patients with previously untreated, unresectable hepatocellular carcinoma.

Dr. Patel on the Role of Entrectinib in Gastrointestinal Malignancies

July 1st 2020

Manish R. Patel, DO, discusses the role of entrectinib in gastrointestinal malignancies.

Nivolumab Demonstrates Survival and Safety Benefit in Frontline HCC With Longer Follow-Up

July 1st 2020

Bruno Sangro, MD, PhD, discusses the efficacy and safety findings from the long-term analysis of the CheckMate-459 trial in advanced hepatocellular carcinoma.

Dr. Sangro on Updated Findings From the CheckMate-459 Trial in Advanced HCC

July 1st 2020

Bruno Sangro, MD, PhD, discusses the updated findings from the phase 3 CheckMate-459 trial, which evaluated the use of nivolumab and sorafenib in the treatment of patients with advanced hepatocellular carcinoma.

FDA Approves First-Line Pembrolizumab for MSI-H/dMMR Metastatic Colorectal Cancer

June 29th 2020

The FDA has approved pembrolizumab (Keytruda) for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer

June 25th 2020

Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.

Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer

June 22nd 2020

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

Pembrolizumab Approved in China for Second-Line PD-L1+ Esophageal Cancer

June 22nd 2020

The National Medical Products Administration in China has approved pembrolizumab for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 as determined by an approved test, following disease progression on 1 prior line of systemic therapy.

Dr. Huey on Challenges Faced With Immunotherapy in HCC

June 20th 2020

Ryan W. Huey, MD, discusses challenges faced with immunotherapy in hepatocellular carcinoma.

Dual Checkpoint Regimen Buoys Prospects for Immunotherapy in HCC

June 18th 2020

The recent approval of nivolumab in combination with ipilimumab demonstrates the utility of dual immunotherapy for patients with hepatocellular carcinoma.

Dr. Janjigian on Pembrolizumab Triplet in HER2+ Esophagogastric Cancer

June 17th 2020

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

FDA Grants Liposomal Irinotecan Fast Track Status for Frontline Metastatic Pancreatic Cancer

June 17th 2020

The FDA has granted a fast track designation to liposomal irinotecan for use in combination with 5-fluorouracil/leucovorin and oxaliplatin as a treatment for patients with previously untreated, unresectable, locally advanced or metastatic pancreatic ductal adenocarcinoma.